In this issue:
Imetelstat for relapsed/erythropoiesis-stimulating agent refractory lower-risk MDS
Extended letermovir prophylaxis in SCT recipients at CMV infection risk
Predicting cytopenias, progression and survival in CCUS
CV toxicities associated with BTEs
First-line ibrutinib and venetoclax for treatment-naïve Waldenströms
CD24 fusion protein for GVHD prevention
Maintenance venetoclax/azacitidine after RIC allogeneic SCT in high-risk MDS/AML
Fedratinib for myelofibrosis after ruxolitinib failure
CEAC vs. BEAM conditioning for autologous SCT in DLBCL
Avatrombopag: early versus chronic ITP
Please login below to download this issue (PDF)